Insilico Medicine Tops 11 Preclinical Candidates in 2026 as Rentosertib Enters Phase III

Insilico Medicine nominated 11 preclinical candidates in the first 10 months of 2026, a new annual record that brings its cumulative total since 2021 to 35, and said Rentosertib (ISM001-055) has entered Phase III trials for idiopathic pulmonary fibrosis. The company announced the figures alongside a schedule of November 2026 keynote appearances, Scienmag reported. Insilico Medicine is a biotechnology company that integrates artificial intelligence and automation into drug discovery and was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under stock code 03696.HK.

Insilico's November 2026 Keynote Schedule

Dr. Jue Wang, Head of Global Business Development, is scheduled to deliver a keynote at the China Healthcare Summit in Shanghai on the afternoon of November 3. Her address will focus on the competitive landscape in what she terms the "era of AI commoditization," arguing that differentiation lies in integrating AI tools into a closed-loop workflow spanning target discovery, molecular generation and clinical validation.

Dr. Feng Ren, Co-CEO and Chief Scientific Officer, will deliver a keynote at the 2026 Future Healthcare Investment Market annual conference in Shanghai on the afternoon of November 4, covering AI-driven small molecule R&D and the path from target identification to preclinical candidate. Dr. Ren will also speak at the Chinese Pharmaceutical Association Medicinal Chemistry Symposium in Nanchang on the morning of November 7, and Dr. Alex Aliper, Co-Founder and President, will join an investor and innovator panel at the Next Generation Medicine Congress 2026 in Dubai on the afternoon of November 7.

Insilico will exhibit at the China International Import Expo from November 5 to 10, 2026, at Booth C1-01, Hall 2.2, debuting holographic projection technology to present its R&D pipeline in three dimensions. The company said Rentosertib is the world's first fully generative AI-discovered drug candidate with first-in-class potential.

Insilico's Partnership and Funding Record

According to akta.pro company records, Insilico signed a collaboration worth more than $2.5 billion with SK Biopharmaceuticals in June 2026 for AI-powered drug discovery in neuroimmune disorders, with single-digit royalties and up to $18 million in upfront and near-term payments. In March 2026 it signed a $2.75 billion collaboration with Eli Lilly, including $115 million upfront, granting Lilly exclusive global rights to preclinical oral therapeutics from Insilico's AI platform. The same records list 12 funding rounds, including a $123 million Series E in March 2025 led by Pudong Chuangtou and Value Partners, and total funding of $624.3 million.

Insilico's Pipeline Milestones Before November

Insilico nominated ISM9546, an oral VAV1 molecular glue degrader, as its 35th preclinical candidate since 2021, PR Newswire reported in October 2026. At ESMO 2026, the company reported first-in-human Phase 1 data for the pan-TEAD inhibitor ISM6331, with 130 mg once daily yielding a 40% objective response rate and 68.2% disease control in heavily pretreated mesothelioma, according to PR Newswire APAC. In September 2026, PR Newswire reported the nomination of ISM1354, an AI-driven small-molecule GIPR antagonist for obesity and related disorders.

Insilico's China International Import Expo Booth

The China International Import Expo runs from November 5 to 10, 2026, at Booth C1-01, Hall 2.2, where Insilico is debuting holographic projection technology for its pipeline.